Limits...
Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.

Niimi K, Murakumo Y, Watanabe N, Kato T, Mii S, Enomoto A, Asai M, Asai N, Yamamoto E, Kajiyama H, Shibata K, Kikkawa F, Takahashi M - Cancer Sci. (2014)

Bottom Line: Enhanced immunoreactivity to REV7 was associated with poor prognosis represented by reduced progression-free survival in advanced stage (stage II-IV) EOC as assessed using Kaplan-Meier curves and log-rank tests.Knockdown of REV7 in CCC cells decreased cell proliferation without affecting cell cycle distribution.In a nude mouse tumor xenograft model, inoculated REV7-knockdown tumors showed significantly reduced tumor volumes after cisplatin treatment compared with those of the control group.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Show MeSH

Related in: MedlinePlus

Immunohistochemical analyses of REV7 expression in epithelial ovarian cancer. (a) Representative images of immunoreactivity for REV7. Images of low REV7 staining levels, with a score of 1 (clear cell) or 0 (serous, mucinous, and endometrioid), are shown on the left; those with high REV7 staining levels, with a score of 3, are shown on the right. Scale bar, 100 μm. (b) Kaplan–Meier curves and log–rank tests for progression-free survival of patients with stage II–IV epithelial ovarian cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317831&req=5

fig01: Immunohistochemical analyses of REV7 expression in epithelial ovarian cancer. (a) Representative images of immunoreactivity for REV7. Images of low REV7 staining levels, with a score of 1 (clear cell) or 0 (serous, mucinous, and endometrioid), are shown on the left; those with high REV7 staining levels, with a score of 3, are shown on the right. Scale bar, 100 μm. (b) Kaplan–Meier curves and log–rank tests for progression-free survival of patients with stage II–IV epithelial ovarian cancer.

Mentions: Formalin-fixed and paraffin-embedded tissues were sliced at a thickness of 4 μm. For antigen retrieval, they were heated in Target Retrieval Solution pH 9.0 (Dako, Copenhagen, Denmark) for 40 min at 98°C. Endogenous peroxidase was inhibited using 3% H2O2 in methanol for 15 min. After blocking with 10% normal goat serum for 10 min at room temperature (RT), sections were incubated with primary antibodies for 90 min at RT and then incubated with the secondary antibody conjugated to HRP-labeled polymer (EnVision+ anti-rabbit; Dako) for 15 min at RT. Reaction products were visualized using diaminobenzidine (Dako), and nuclei were counterstained with hematoxylin. The staining intensity of REV7 was scored as 0 (negative), 1 (weak), 2 (medium), or 3 (strong) and then further classified into two categories: low, expression scores 0 and 1; or high, expression scores 2 and 3 (Fig.1a, see Data S1 for antibody information). The REV7 expression levels were evaluated by two independent blinded observers.


Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.

Niimi K, Murakumo Y, Watanabe N, Kato T, Mii S, Enomoto A, Asai M, Asai N, Yamamoto E, Kajiyama H, Shibata K, Kikkawa F, Takahashi M - Cancer Sci. (2014)

Immunohistochemical analyses of REV7 expression in epithelial ovarian cancer. (a) Representative images of immunoreactivity for REV7. Images of low REV7 staining levels, with a score of 1 (clear cell) or 0 (serous, mucinous, and endometrioid), are shown on the left; those with high REV7 staining levels, with a score of 3, are shown on the right. Scale bar, 100 μm. (b) Kaplan–Meier curves and log–rank tests for progression-free survival of patients with stage II–IV epithelial ovarian cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317831&req=5

fig01: Immunohistochemical analyses of REV7 expression in epithelial ovarian cancer. (a) Representative images of immunoreactivity for REV7. Images of low REV7 staining levels, with a score of 1 (clear cell) or 0 (serous, mucinous, and endometrioid), are shown on the left; those with high REV7 staining levels, with a score of 3, are shown on the right. Scale bar, 100 μm. (b) Kaplan–Meier curves and log–rank tests for progression-free survival of patients with stage II–IV epithelial ovarian cancer.
Mentions: Formalin-fixed and paraffin-embedded tissues were sliced at a thickness of 4 μm. For antigen retrieval, they were heated in Target Retrieval Solution pH 9.0 (Dako, Copenhagen, Denmark) for 40 min at 98°C. Endogenous peroxidase was inhibited using 3% H2O2 in methanol for 15 min. After blocking with 10% normal goat serum for 10 min at room temperature (RT), sections were incubated with primary antibodies for 90 min at RT and then incubated with the secondary antibody conjugated to HRP-labeled polymer (EnVision+ anti-rabbit; Dako) for 15 min at RT. Reaction products were visualized using diaminobenzidine (Dako), and nuclei were counterstained with hematoxylin. The staining intensity of REV7 was scored as 0 (negative), 1 (weak), 2 (medium), or 3 (strong) and then further classified into two categories: low, expression scores 0 and 1; or high, expression scores 2 and 3 (Fig.1a, see Data S1 for antibody information). The REV7 expression levels were evaluated by two independent blinded observers.

Bottom Line: Enhanced immunoreactivity to REV7 was associated with poor prognosis represented by reduced progression-free survival in advanced stage (stage II-IV) EOC as assessed using Kaplan-Meier curves and log-rank tests.Knockdown of REV7 in CCC cells decreased cell proliferation without affecting cell cycle distribution.In a nude mouse tumor xenograft model, inoculated REV7-knockdown tumors showed significantly reduced tumor volumes after cisplatin treatment compared with those of the control group.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Show MeSH
Related in: MedlinePlus